Survodutide achieved up to 13.1% weight loss vs 3.1% with placebo at 76 weeks in adults with obesity and T2D in the phase 3 SYNCHRONIZE-2 trial.
|Articles|December 13, 2014
Merck's Ebola Vaccine Trial Halted
Reuters has reported that Merck's Ebola vaccine trial has been temporarily halted.
Advertisement
A clinical trial of the Ebola vaccine by Merck and NewLink has been interrupted in all 59 volunteers in Geneva a week early "as a measure of precaution" after 4 patients complained of joint pains in hands and feet, the University of Geneva Hospital said on Thursday.
"They are all fine and being monitored regularly by the medical team leading the study," the hospital said in a statement.
The human safety trials are due to resume on January 5 in up to 15 volunteers after checks to ensure that the joint pain symptoms were "benign and temporary," the hospital said.
Original report by Reuters:
Advertisement
Related to this article
AASM urges CMS to reject proposed 2027 Medicare conversion factor cuts of 1.19% to 1.68% and revise sleep testing and remote monitoring policies.
A rare case of soft-tissue sarcoma spreading to the heart shows how multimodal imaging guided diagnosis and care in a 36-year-old man.
A higher ratio of red blood cell distribution width to albumin was tied to greater all-cause, cardiovascular, and cancer mortality in adults with CKD.
A meta-analysis of 22 studies found steatotic liver disease in about three-quarters of patients with sleep-disordered breathing.
FDA accepted United Therapeutics' sNDA for inhaled treprostinil in IPF. Here's what it could mean for patient access, coverage, and costs
Sustainable models require asking what a result shows, what design produced it, and whether the design was built to measure value or just produce a number.
CAR T-cell therapy must be treated as a complete "vein-to-vein" episode, with community practices needing to take control of cases for a period of time.
Advertisement
Advertisement
Trending on AJMC
1
Retatrutide Yields Up to 20.8% Weight Loss in Obesity With T2D
2
IRA, 340B, Medicaid: The Policy Pressures on Community Oncology
3
CMS Projects 16.5% Drop in 2027 Medicare Advantage Premiums
4
Drug Price Drives Value of MASH Therapies More Than Efficacy
5